{"DataElement":{"publicId":"2185777","version":"1","preferredName":"Hormone Therapy Administered Type","preferredDefinition":"the type of hormone therapy being administered.","longName":"HORMONTX_ADMIN_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014198","version":"1","preferredName":"Hormone Therapy Administered","preferredDefinition":"the administered hormone therapy to an individual.","longName":"HORMONTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177094","version":"1","preferredName":"Hormonal Therapy","preferredDefinition":"Treatment that adds, blocks, or removes hormones.  For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels.  To slow or stop the growth of certain cancers (such as prostate and breast cancer), hormones may be given to block the body's natural hormones.  Sometimes surgery is needed to remove the source of hormones.","longName":"Hormonal Therapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A74-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5ECF6FC-A421-09B6-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-05","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-02-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2185778","version":"1","preferredName":"Hormone Therapy Administration Type","preferredDefinition":"the type of hormonal therapy being administered.","longName":"HORMONTX_ADMIN_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SERM","valueDescription":"SERM","ValueMeaning":{"publicId":"2571014","version":"1","preferredName":"SERM","longName":"2571014","preferredDefinition":"selective estrogen-receptor modulator","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E273-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"CAMPBELB","dateModified":"2004-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DEA3A42E-36BC-0316-E034-0003BA12F5E7","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovarian suppression","valueDescription":"Ovarian suppression","ValueMeaning":{"publicId":"2571016","version":"1","preferredName":"Ovarian suppression","longName":"2571016","preferredDefinition":"Ovarian suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E275-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"CAMPBELB","dateModified":"2004-07-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DEA3A42E-36C4-0316-E034-0003BA12F5E7","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Aromatase inhibitor","valueDescription":"Aromatase inhibitor","ValueMeaning":{"publicId":"2571015","version":"1","preferredName":"Aromatase inhibitor","longName":"2571015","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E274-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2007-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DEA3A42E-36C0-0316-E034-0003BA12F5E7","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"Tamoxifen","ValueMeaning":{"publicId":"2897675","version":"1","preferredName":"Tamoxifen","longName":"2897675","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB2B-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D707821-E0AF-A70D-E040-BB89AD433BD3","beginDate":"2011-03-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-01","modifiedBy":"ONEDATA","dateModified":"2011-03-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3089560","version":"1","preferredName":"Other","longName":"3089560","preferredDefinition":"Other treatment cannot be appropriately assigned to specific data item (i.e. phlebotomy, transfusion, and aspirin or other disease modifying agent). Use for hematopoietic diseases.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87063ADB-2EE9-3A83-E040-BB89AD430877","latestVersionIndicator":"Yes","beginDate":"2010-05-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-05-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D707821-E0B9-A70D-E040-BB89AD433BD3","beginDate":"2011-03-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-01","modifiedBy":"ONEDATA","dateModified":"2011-03-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DEA39D83-8035-016D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2011-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171062","version":"1","longName":"RTOG-1005","context":"NRG"}]}],"AlternateNames":[{"name":"HORMONTX_ADMIN_TP","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"CRF","type":"Alternate Question Text","description":"If currently receiving","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"If yes","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Preferred Question Text","description":"Type of anti endocrine therapy","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DEA39CB0-6D02-03C5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}